Advertisement
Canada markets open in 26 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7371
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    82.60
    +1.25 (+1.54%)
     
  • Bitcoin CAD

    96,119.48
    +498.75 (+0.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,230.80
    +18.10 (+0.82%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.2160
    +0.0200 (+0.48%)
     
  • NASDAQ futures

    18,488.50
    -15.25 (-0.08%)
     
  • VOLATILITY

    13.00
    +0.22 (+1.72%)
     
  • FTSE

    7,955.57
    +23.59 (+0.30%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6813
    +0.0008 (+0.12%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

New York, New York--(Newsfile Corp. - May 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information go to:

https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=15788&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

ADVERTISEMENT

If you suffered a loss in FibroGen you have until June 11, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83887